INSYS Therapeutics, Inc. – Fentanyl Manufacturer Chased into Chapter 11 as Exposure to Opioid Crisis Becomes Untenable

June 10, 2019 − INSYS Therapeutics, Inc. (f/k/a Neopharm Inc.) and six affiliated Debtors ("INSYS" or the "Debtors") filed for Chapter 11 protection with the U.S. Bankruptcy Court in the District of Delaware, lead case number 19-11292. The Company,  a specialty pharmaceutical development and distribution company with a heavy reliance on opioid products, is represented…